Life Science Investing BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Life Science Investing BioAtla's Mecbotamab Vedotin , an AXL-targeting ADC, Demonstrates a Median Overall Survival of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
Life Science Investing BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
Life Science Investing BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma at the Annual Conference of the International Papillomavirus Society
Life Science Investing BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
Life Science Investing BioAtla to Present Clinical Data for Mecbotamab Vedotin in Soft Tissue Sarcoma at SITC 2025
Life Science Investing BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA
Allied Critical Metals Announces Material Increase to Mineral Resource Estimate at Borralha Tungsten Project in Northern Portugal
